GSK plc
GSK · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.44 | 0.00 | -0.36 | -2.45 |
| FCF Yield | 6.48% | 10.60% | 11.55% | 10.15% |
| EV / EBITDA | 10.26 | 8.62 | 8.81 | 12.20 |
| Quality | ||||
| ROIC | 8.51% | 11.37% | 13.62% | 5.32% |
| Gross Margin | 71.16% | 71.76% | 67.42% | 66.95% |
| Cash Conversion Ratio | 2.22 | 1.29 | 1.49 | 2.26 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.28% | 7.09% | 6.39% | 29,121,073.52% |
| Free Cash Flow Growth | -42.92% | -7.33% | 27.46% | -18.44% |
| Safety | ||||
| Net Debt / EBITDA | 1.99 | 2.12 | 2.01 | 4.16 |
| Interest Coverage | 6.11 | 8.70 | 7.52 | 5.56 |
| Efficiency | ||||
| Inventory Turnover | 1.60 | 1.22 | 1.86 | 1.04 |
| Cash Conversion Cycle | 158.82 | 210.33 | 126.30 | 236.35 |